Monday March 4, 2013 0 comments
WESTMINSTER - Cerapedics Inc., a medical device company pioneering the use of peptide-enhanced bone grafting materials in spine, trauma and orthopedic surgery, announced it has treated more than 10,000 patients with its i-FACTOR Peptide Enhanced Bone Graft product since 2008.
The product is still in the investigational stage of FDA approval in the U.S. but has been available outside the U.S. since late 2008.
"This is a significant achievement and milestone for the company and confirms that i-FACTOR bone graft can provide a viable treatment option to both surgeons and patients looking for an alternative to either autograft harvesting or expensive growth factor technologies," said Steve McAdoo, Cerapedics vice president of marketing.
The company's i-FACTOR bone graft received the CE Mark in late 2008 and has been used in more than 10,000 surgeries worldwide since then.
The product is now available in both a putty and flexible strip form in more than 20 countries outside the U.S.
The product is currently being evaluated in the U.S. as part of an Investigational Device Exemption Clinical Study in the cervical spine.
For more information, visit www.cerapedics.com.